Colistimethate sodium (CMS)

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Ain Shams University, Qilu Hospital of Shandong University

Conditions

Bacterial InfectionsCentral Nervous System InfectionsVentilator-Associated Pneumonia (VAP)

Phase 3

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

CompletedNCT02452047

Merck Sharp & Dohme LLCBacterial Infections

Start: 2015-08-21End: 2017-09-18Updated: 2018-10-19

Unknown Phase

Comparing Tigecycline Vs. Colistimethate in CNS Infections

Not yet recruitingNCT06702943

Ain Shams UniversityCentral Nervous System Infections

Start: 2024-12-01End: 2027-06-30Target: 70Updated: 2024-11-25

Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

RecruitingNCT06834971

Qilu Hospital of Shandong UniversityVentilator-Associated Pneumonia (VAP)

Start: 2025-07-15End: 2026-12-31Target: 508Updated: 2025-07-15

Related Papers

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.

2020-04-2128 citations

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

Open Forum Infectious Diseases2020-02-1927 citations

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Clinical Infectious Diseases2019-06-25383 citations

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections

Open Forum Infectious Diseases2018-11-014 citations

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections

Open Forum Infectious Diseases2018-11-01